Insulet enrolled the first participant in a study of its fully closed-loop automated insulin delivery system for type 2 ...

Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve ...

Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.

Fully Closed-Loop System Feasibility Study to be presented at Insulet Symposium and in e-Poster during ATTD 2026 Real World Evidence of Settings Optimization in Omnipod 5 Users will also be shared ...

New system combines Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and the Netherlands ...

Compared with net loss of $130.6 million in Q1 2025 Tandem Diabetes Care plans to file a 510(k) submission with the Food and ...

Insulet has begun enrolling up to 350 adults with type 2 diabetes in its pivotal EVOLVE trial, testing a fully closed-loop automated insulin delivery system that removes the need for user-initiated ...

Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod®brand of products, has shared new clinical evidence related to the ...